Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

B16 and 4T1 cell lines with decitabine treatment

ABSTRACT: B16 and 4T1 cell lines with decitabine treatment

PROVIDER: PRJNA873582 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR21201200_1.fastq.gz	Fastqsanger.gz
	SRR21201200_2.fastq.gz	Fastqsanger.gz
	SRR21201201_1.fastq.gz	Fastqsanger.gz
	SRR21201201_2.fastq.gz	Fastqsanger.gz
	SRR21201202_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 72

Similar Datasets

Chromatin accessibility in B16 and 4T1 cell lines with decitabine treatment [ATAC-seq]

Project description:The goal of ATAC-seq is to identify the open chromatin regions in the B16 and 4T1 cells after Decitabine treatment. Three biological replicates were assigned for each group and in total 12 groups were prepared for ATAC-seq libraries. We mapped about 30-100 million reads per sample to M.musculus (mm10) with bowtie2 workflow. Open chromatin regions were deducted by ChIPseeker with corrected p < 0.05. Our results showed M.Musculus have dispartate chromatin accessibility after Decitabine treatment

2024-06-30 | GSE212026 | GEO

Chromatin accessibility in B16 and 4T1 cell lines with decitabine treatment [ATAC-seq]

Project description:Chromatin accessibility in B16 and 4T1 cell lines with decitabine treatment [ATAC-seq]

| PRJNA873588 | ENA

WGS for B16-OVA and 4T1 murine cancer cell lines

Project description:Whole Genome Sequencing of the murine breast cancer cell line 4T1 and of the murine melanoma cell line B16-ova was carried out with the aim of identifying somatic mutations. We also ran deep Mass Spectrometry proteomics analysis on the same cell lines, aiming to determine which somatic mutations carry over to the protein expression level. Further, we tested these cancer specific protein epitopes (putative neoantigens) for immunogenicity using mouse models. Finally, the putative neoantigens that showed good immunogenic potential were used in tumor growth control experiments with mice engrafted with the two tumor cell lines. In these experiments we tested whether cancer vaccines based on individual neoantigen peptides (MHC-I) restricted the growth of the tumor compared to adequate controls. The overall aim of the project is to validate the ability of our multi-omics/bioinformatics pipeline to identify and deliver neoantigens that can be used to suppress tumor growth. File names Sample names P10859_101_S1_L001_R1_001_BHKWV3CCXY 4T1_S1_L001_R1_001_BHKWV3CCXY P10859_101_S1_L001_R2_001_BHKWV3CCXY 4T1_S1_L001_R2_001_BHKWV3CCXY P10859_101_S1_L002_R1_001_BHKWV3CCXY 4T1_S1_L002_R1_001_BHKWV3CCXY P10859_101_S1_L002_R2_001_BHKWV3CCXY 4T1_S1_L002_R2_001_BHKWV3CCXY P10859_102_S2_L003_R1_001_BHKWV3CCXY B16-OVA_S2_L003_R1_001_BHKWV3CCXY P10859_102_S2_L003_R2_001_BHKWV3CCXY B16-OVA_S2_L003_R2_001_BHKWV3CCXY P10859_102_S2_L004_R1_001_BHKWV3CCXY B16-OVA_S2_L004_R1_001_BHKWV3CCXY P10859_102_S2_L004_R2_001_BHKWV3CCXY B16-OVA_S2_L004_R2_001_BHKWV3CCXY

2024-01-31 | E-MTAB-13635 | biostudies-arrayexpress

Transcriptome analysis in B16F10 and 4T1 cell lines with decitabine treatment [RNA-seq]

Project description:Transcriptome analysis in B16F10 and 4T1 cell lines with decitabine treatment [RNA-seq]

| PRJNA873589 | ENA

Transcriptome analysis in B16F10 and 4T1 cell lines with decitabine treatment [RNA-seq]

Project description:The goal of RNA-seq is to identify the differential expressed genes in the B16F10 and 4T1 cells after Decitabine treatment. Three biological replicates were assigned for each group and in total 12 groups were prepared for RNA-seq libraries with 300 ng mRNA as starting materials using NEXTflex Illumina qRNA-Seq Library Prep Kit (Bioo Scientific). We mapped over 60 million reads per sample to mouse genome (mm10) with RSEM workflow. P-values of differential expression were adjusted for multiple-hypothesis testing using False Discovery Rate (FDR) method.

2024-06-30 | GSE212027 | GEO

RNAseq for B16-OVA and 4T1 murine cancer cell lines

Project description:RNAseq for B16-OVA and 4T1 murine cancer cell lines

| PRJEB76227 | ENA

WGS for B16-OVA and 4T1 murine cancer cell lines

Project description:WGS for B16-OVA and 4T1 murine cancer cell lines

| PRJEB71410 | ENA

RNAseq for B16-OVA and 4T1 murine cancer cell lines

Project description:RNA Sequencing of the murine breast cancer cell line 4T1 and of the murine melanoma cell line B16-ova was carried out with the aim of establishing the complete transcriptome of these cell lines. Because these are cancer cells and we expect a lot of aberrant splicing, we carried out de novo assembly (genome guided) of the transcripts. We also ran deep Mass Spectrometry proteomics analysis on the same cell lines, aiming to determine which aberrant transcripts carry over to the protein expression level. Further, we tested these cancer specific protein epitopes (putative neoantigens) for immunogenicity using mouse models. Finally, the putative neoantigens that showed good immunogenic potential were used in tumor growth control experiments with mice engrafted with the two tumor cell lines. In these experiments we tested whether cancer vaccines based on individual neoantigen peptides (MHC-I) restricted the growth of the tumor compared to adequate controls. The overall aim of the project is to validate the ability of our multi-omics/bioinformatics pipeline to identify and deliver neoantigens that can be used to suppress tumor growth.

2024-06-30 | E-MTAB-14130 | biostudies-arrayexpress

B16 and 4T1 cell lines with decitabine treatment

Project description:This SuperSeries is composed of the SubSeries listed below.

2024-06-30 | GSE212029 | GEO